Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics

Suberoylanilide hydroxamic acid (SAHA), a pan HDAC inhibitor, has been approved by the Food and Drug Administration (FDA) to treat cutaneous T cell lymphoma (CTCL). Nevertheless, the mechanisms underlying the therapeutic effects of SAHA on tumors are yet not fully understood. Protein phosphorylation...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Cell Dev Biol
Auteurs principaux: Huang, Huichao, Fu, Ying, Zhang, Ye, Peng, Fang, Lu, Miaolong, Feng, Yilu, Chen, Lin, Chen, Zhuchu, Li, Maoyu, Chen, Yongheng
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2020
Sujets:
Cell and Developmental Biology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7726116/
https://ncbi.nlm.nih.gov/pubmed/33324635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2020.577784
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires